Intended Audience:PCPs (nurses, PA)

Bayer TA Rationale for Educational Support:

1. HF Disease Burden, with focus on HFmrEF and HFpEF (LVEF ≥40%)(highlight contemporary disease definitions, understanding of pathophysiology, etc.)
2. Importance of co-morbid conditions
3. Current SoC for patients with HFmrEF and HFpEF, Treatment gaps, and residual risk
4. Unique properties of non-steroidal MRAs vs steroidal MRAs
5. Efficacy Data
   1. FINEARTS-HF trial and relevant subanalyses
   2. FINEHEART trial
6. Safety and tolerability

Intended Audience: Cardiologist, Endocrinologist, Nephrologist, Internal Medicine

Bayer TA Rationale for Educational Support: 

Rationale for Educational Support: 

1. HFmrEF/HFpEF (LVEF ≥40%) disease burden, with focus on epidemiology, clinical outcomes, current understanding of pathophysiology
2. Current SoC for patients with HFmrEF and HFpEF, real world utilization of recommended therapies, and residual risk
3. Unique properties of non-steroidal MRAs vs steroidal MRAs
4. Efficacy data
   1. FINEARTS-HF trial and relevant subanalyses
   2. FINEHEART trialMRS vs SMRA
5. Safety and tolerability

Preferred Format:

• Enduring
• Downloadable slides
• Incorporation of social media outreach (You-Tube, FaceBook, Spotify, LinkedIn, Twitter)
• Podcast
• Live Virtual

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning Objectives
• Proposed Faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan
• Detailed budget (please use the template available on the website)

Provider Justification:

Copy of most recent accreditation letter and status

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References:

Publication References

1. Solomon et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. NEJM. DOI: 10.1056/NEJMoa2407107
2. Desai AS et al. Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08452-3. doi: 10.1016/j.jacc.2024.09.004. Online ahead of print.
3. Vaduganathan et al. Time to Significant Benefit of Finerenone in Patients With Heart Failure. J Am Coll Cardiol. 2024 Sep 26:S0735-1097(24)08512-7. doi: 10.1016/j.jacc.2024.09.018. Online ahead of print.
4. Vaduganathan M et al. Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 2024 Sep 28. doi: 10.1161/CIRCULATIONAHA.124.072055. Online ahead of print.
5. Docherty KF et al. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial. Circulation. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.072011. Online ahead of print.
6. Chimura M et al. Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF. Circ Heart Fail. 2024 Sep 29. doi: 10.1161/CIRCHEARTFAILURE.124.012437. Online ahead of print.
7. Chang J et al. Mineralocorticoid Antagonism in Heart Failure: Established and Emerging Therapeutic Role. JACC Heart Fail. 2024 Sep 1:S2213-1779(24)00606-1. doi: 10.1016/j.jchf.2024.08.007. Online ahead of print.